CLINICAL TRIALS PROFILE FOR NARCAN

All Clinical Trials for NARCAN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00335517 ↗	Safety and Efficacy of DepoDur in Lumbar Spine Surgery Patients	Completed	EKR Therapeutics, Inc	N/A	2006-06-01	The purpose of the study is to help determine the appropriate dose of DepoDur for use in spinal surgery. The study will also assess the safety of this drug in this patient population.
NCT00335517 ↗	Safety and Efficacy of DepoDur in Lumbar Spine Surgery Patients	Completed	University of Rochester	N/A	2006-06-01	The purpose of the study is to help determine the appropriate dose of DepoDur for use in spinal surgery. The study will also assess the safety of this drug in this patient population.
NCT00678145 ↗	Mechanisms of Hypoglycemia Associated Autonomic Failure	Active, not recruiting	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 2	2008-03-01	Intensive glucose control in type 1 diabetes mellitus (T1DM) is associated with clear health benefits (1). However, despite development of insulin analogs, pump/multi-dose treatment and continuous glucose monitoring, maintaining near-normal glycemia remains an elusive goal for most patients, in large part owing to the risk of hypoglycemia. T1DM patients are susceptible to hypoglycemia due to defective counterregulatory responses (CR) characterized by: 1) deficient glucagon release during impending/early hypoglycemia; 2) additional hypoglycemia-associated autonomic failure (HAAF) and exercise-associated autonomic failure (EAAF) that blunt the sympathoadrenal responses to hypoglycemia following repeated episodes of hypoglycemia or exercise as well as degrading other CR; and 3) hypoglycemia unawareness (HU), lowering the threshold for symptoms that trigger behavioral responses (e.g. eating). Thus, the risk of hypoglycemia in T1DM impedes ideal insulin treatment and leads to defaulting to suboptimal glycemic control (2). There are two approaches that could resolve this important clinical problem: 1) perfection of glucose sensing and insulin and glucagon delivery approaches (bioengineered or cell-based) that mimic normal islet function and precisely regulate glucose continuously, or 2) a drug to enhance or normalize the pattern of CR to hypoglycemia. Despite much research and important advances in the field, neither islet transplantation nor biosensor devices have emerged as viable long-term solutions for the majority of patients (3, 4). Over the past several years, our lab has explored the approach of enhancing CR by examining mechanisms responsible for HAAF/EAAF and searching for potential pharmacological methods to modulate the CR to hypoglycemia (5-11). Our work has led to a paradigm shift in the field of hypoglycemia, exemplified by the novel hypothesis and published experimental data supporting a role for opioid signaling that resulted in the initiation of exploratory clinical trials by other research groups.
NCT00678145 ↗	Mechanisms of Hypoglycemia Associated Autonomic Failure	Active, not recruiting	National Institutes of Health (NIH)	Phase 2	2008-03-01	Intensive glucose control in type 1 diabetes mellitus (T1DM) is associated with clear health benefits (1). However, despite development of insulin analogs, pump/multi-dose treatment and continuous glucose monitoring, maintaining near-normal glycemia remains an elusive goal for most patients, in large part owing to the risk of hypoglycemia. T1DM patients are susceptible to hypoglycemia due to defective counterregulatory responses (CR) characterized by: 1) deficient glucagon release during impending/early hypoglycemia; 2) additional hypoglycemia-associated autonomic failure (HAAF) and exercise-associated autonomic failure (EAAF) that blunt the sympathoadrenal responses to hypoglycemia following repeated episodes of hypoglycemia or exercise as well as degrading other CR; and 3) hypoglycemia unawareness (HU), lowering the threshold for symptoms that trigger behavioral responses (e.g. eating). Thus, the risk of hypoglycemia in T1DM impedes ideal insulin treatment and leads to defaulting to suboptimal glycemic control (2). There are two approaches that could resolve this important clinical problem: 1) perfection of glucose sensing and insulin and glucagon delivery approaches (bioengineered or cell-based) that mimic normal islet function and precisely regulate glucose continuously, or 2) a drug to enhance or normalize the pattern of CR to hypoglycemia. Despite much research and important advances in the field, neither islet transplantation nor biosensor devices have emerged as viable long-term solutions for the majority of patients (3, 4). Over the past several years, our lab has explored the approach of enhancing CR by examining mechanisms responsible for HAAF/EAAF and searching for potential pharmacological methods to modulate the CR to hypoglycemia (5-11). Our work has led to a paradigm shift in the field of hypoglycemia, exemplified by the novel hypothesis and published experimental data supporting a role for opioid signaling that resulted in the initiation of exploratory clinical trials by other research groups.

Clinical Trial Conditions for NARCAN

Condition Name

Condition Name for NARCAN
Intervention	Trials
Opioid Overdose	3
Opioid-use Disorder	3
Drug Overdose	2
Opioid Use Disorder	2

Condition MeSH

Condition MeSH for NARCAN
Intervention	Trials
Opioid-Related Disorders	6
Opiate Overdose	4
Drug Overdose	3
Brain Death	2

Clinical Trial Locations for NARCAN

Trials by Country

Trials by Country for NARCAN
Location	Trials
United States	25
Thailand	1

Trials by US State

Trials by US State for NARCAN
Location	Trials
Ohio	4
Tennessee	3
California	3
Illinois	2
Missouri	2

Clinical Trial Progress for NARCAN

Clinical Trial Phase

Clinical Trial Phase for NARCAN
Clinical Trial Phase	Trials
PHASE3	1
PHASE1	1
Phase 4	4

Clinical Trial Status

Clinical Trial Status for NARCAN
Clinical Trial Phase	Trials
Completed	10
Recruiting	4
Terminated	3

Clinical Trial Sponsors for NARCAN

Sponsor Name

Sponsor Name for NARCAN
Sponsor	Trials
National Institute on Drug Abuse (NIDA)	5
University of California, San Francisco	3
Vanderbilt University Medical Center	3

Sponsor Type

Sponsor Type for NARCAN
Sponsor	Trials
Other	25
NIH	7
Industry	3

Last updated: July 28, 2026

Narcan (naloxone) clinical trials update, market analysis, and projection: how sales, exclusivity, and generic/biosimilar risk shape the next 5 years

Narcan (naloxone) is the brand anchor for reversal of opioid-induced respiratory depression. In the US, the commercial market is increasingly defined by (1) rapid-switch, class-level demand for opioid overdose rescue products, (2) payer substitution among FDA-approved naloxone delivery formats (intranasal vs auto-injector vs injectable), and (3) manufacturing and supply-chain execution. From a clinical development perspective, current activity is centered on optimization rather than paradigm-shift science: delivery-device performance, formulation tweaks, and label-expansion studies designed to support broader use settings and dosing workflows.

What is Narcan’s current FDA status, Orange Book standing, and exclusivity clock?

Narcan is an FDA-approved naloxone product with multiple dosage forms and brand-associated labeling for emergency reversal of opioid overdose. The practical regulatory “clock” for US competition is driven less by classic single-product patent monopolies and more by the breadth of naloxone approvals and the ability of generic manufacturers to enter once the relevant patent and exclusivity barriers clear.

What products compete directly with Narcan in the naloxone rescue category?

The competitive set typically includes other FDA-approved naloxone formulations and delivery devices used by emergency responders, caregivers, and opioid treatment settings, including:

• Intranasal naloxone brands and their authorized generics
• Naloxone auto-injector products for intramuscular use
• Injectable naloxone presentations used in EMS and inpatient settings

What does “Orange Book status” drive for Narcan?

For market planning, Orange Book listings determine whether generic substitution is constrained by:

• Unexpired composition-of-matter or formulation patents
• Method-of-use patents (less common for naloxone class products)
• Device-related IP tied to delivery system design
• Exclusivity that can block generic approval even absent a patent (rare but relevant for specific NDCs)

Because naloxone is an established active ingredient with multiple approved products, market entry risk is usually tied to the ability to design around brand-specific patents and to meet the FDA’s bioequivalence and device performance requirements, rather than to novel clinical superiority.

Which Narcan clinical trials are active, recruiting, or recently completed?

Clinical trials for naloxone products are typically structured around:

• Device usability endpoints (time-to-effect proxies, correct administration rates)
• Pharmacokinetic comparability for formulation changes
• Label support for repeat dosing guidance and caregiver administration
• Human factors studies for intranasal devices

A clinical trial update for Narcan must be grounded in trial registry records (ClinicalTrials.gov) and submission timelines tied to FDA label changes. This analysis cannot produce a complete and accurate trial-by-trial status table without verified registry data and dates.

How do device and formulation changes affect Narcan’s pipeline value?

Narcan’s value proposition is tightly coupled to delivery device usability and reliability under real-world constraints (speed, correct spray/actuation, environmental tolerance, training requirements). Development programs that are commercially meaningful tend to:

• Reduce administration errors via human factors-driven interface design
• Improve intranasal spray consistency (volume delivery, particle dispersion)
• Optimize concentration and excipient systems for stability and shelf life
• Support broader prescribing and distribution channels through dosing workflow improvements

For market investors, device iteration is often lower risk than new chemical entity development, but it can still create IP islands around:

• Device mechanics and sensing
• Formulation process parameters
• Specific fill-finish and assembly tolerances

What patents protect Narcan, and how strong is the patent estate versus generic naloxone?

Naloxone is a mature molecule, so “patent estate strength” for Narcan is usually concentrated in:

• Formulation patents for specific intranasal compositions
• Method-of-manufacture claims for stability or spray characteristics
• Device and delivery system patents for specific autoinjector or intranasal components
• Labeling and use-related IP (less frequently enforceable than formulation/device claims)

A defensible patent strength and expiration map requires listing the Orange Book patents for each Narcan NDC (with assignees and expiration dates) and cross-referencing any litigation settlements or Paragraph IV history. Without verified patent and NDC-level data, this cannot be completed to an accurate standard.

When does Narcan lose exclusivity in the US, and what entry risks exist for generics?

For a class like naloxone, entry risk is usually governed by:

• Patent expirations tied to the specific dosage form (intranasal vs injectable vs auto-injector)
• The timing of FDA approval for generics/authorized generics that can reference earlier safety and efficacy packages
• Any managed access or distributor agreements that affect near-term uptake even after legal entry

A complete exclusivity timeline must be NDC-specific (each presentation can have different listed patents and regulatory exclusivity). Without those NDC-to-patent mappings, a precise launch-risk view would be incomplete.

What Paragraph IV challenges or patent litigations affect Narcan?

Patent litigation for naloxone generally arises when a generic manufacturer seeks approval for a competing NDC and challenges listed patents. The commercial impact depends on:

• Case schedules (injunction risk versus modified approval timelines)
• Settlement terms (designed launch dates, carve-outs, supply agreements)
• Whether disputes cover composition, formulation, or device-related claims

A litigation-impact section requires verified docket and settlement documentation, including case numbers, courts, and settlement entry dates. Without source-backed case data, this cannot be produced accurately.

What is Narcan’s revenue exposure: where is the money coming from and what drives demand?

Narcan demand is primarily driven by:

• Public health and opioid overdose initiatives (ED stocking, first responder deployment, pharmacy channel distribution)
• Institutional purchasing cycles (EMS, correctional facilities, schools, workplace programs)
• Payer reimbursement dynamics by setting (commercial and government formularies)
• Substitution pressure across naloxone delivery formats

Market sizing and forecasts depend on:

• Total naloxone US unit volumes and ASP by dosage form
• Brand share trends versus competing products
• Contracted pricing and rebate patterns in institutional channels

A credible five-year projection requires historical unit/sales series and competitive share data that is not provided here. This analysis cannot generate accurate projections without those inputs.

How does Narcan compare with competing naloxone products on efficacy, usability, and market adoption?

Clinical efficacy is broadly class-consistent: naloxone is a competitive opioid antagonist with established reversal of opioid-induced respiratory depression. The differentiators that matter for buying decisions and adoption include:

• Delivery form suitability (intranasal for rapid caregiver administration vs injectable for EMS protocols)
• Training burden and human factors outcomes
• Storage and readiness (temperature ranges, shelf-life, shelf inventory practices)
• Unit economics and reimbursement coverage

A side-by-side comparison table that impacts commercial strategy requires verified performance metrics and labeling, plus current market share by product and channel.

How do US payer policies and reimbursement affect Narcan’s outlook?

For naloxone, reimbursement and formulary placement determine whether:

• A branded NDC maintains restricted access (fewer covered alternatives)
• Plans require step therapy or preferred product substitution
• Mandates for opioid overdose rescue kits influence channel pull-through

Forecasting requires:

• Formularies by plan type (commercial PBM coverage, Medicaid state coverage patterns)
• Medicare Part D coverage behavior for emergency products
• Institutional contract procurement rules

Without payer-level dataset inputs, a precise outlook is not possible.

What is the five-year market projection for Narcan (US and ex-US), and what scenarios change the numbers?

A five-year projection must be built from:

• Baseline market size for naloxone rescue products by dosage form
• Historical growth or decline rates for each category
• Expected legal entry timing for competing products in each NDC/presentation
• Expected share shifts post-entry (brand share erosion and price pressure)
• Manufacturing capacity expansions and supply constraints

This cannot be completed with required accuracy without a sourced baseline and competitive entry schedule.

Key Takeaways

• Narcan’s commercial trajectory is shaped more by naloxone category competition and device usability than by new clinical efficacy breakthroughs.
• The decisive drivers for market outlook are NDC-specific exclusivity, patent expiration, and device/formulation IP enforceability.
• Clinical development activity is likely focused on label and usability support, where commercial impact depends on FDA label expansions and adoption through institutions and payers.
• A precise market projection requires sourced historical sales, unit volumes, ASP/reimbursement patterns, and a NDC-to-patent/exclusivity and litigation map.

FAQs

1. What dosage forms of naloxone are most used by EMS versus home caregivers?
2. How do intranasal versus auto-injector naloxone devices differ in real-world administration success metrics?
3. What legal and regulatory steps determine when a generic naloxone NDC can launch in the US?
4. How do Medicaid and state-level opioid overdose initiatives affect naloxone distribution volumes?
5. Which patent claim types (formulation, device, manufacturing method) most often drive naloxone litigation outcomes?

References

1. ClinicalTrials.gov. (n.d.). Search results for naloxone and intranasal naloxone trials.
2. FDA Orange Book. (n.d.). Drug Products (Approved Drug Products with Therapeutic Equivalence Evaluations) for naloxone.